10-K: QHSLab, Inc. Reports Full Year 2023 Results, Cites Ongoing Concerns

QHSLab, Inc. reported a net loss for 2023 and highlighted ongoing concerns about its ability to continue as a going concern.

Summary

• QHSLab, Inc., a medical device technology and SaaS company, reported a net loss of $468,362 for the year ended December 31, 2023, compared to a net loss of $996,001 in 2022.
• The company's revenue increased to $1,408,995 in 2023 from $1,243,186 in 2022, primarily driven by sales of allergy diagnostic kits and immunotherapy treatments.
• The company's gross profit increased to $793,607 in 2023 from $619,519 in 2022, with a gross margin of 56.3% in 2023 compared to 49.8% in 2022.
• Operating expenses decreased to $1,033,765 in 2023 from $1,180,058 in 2022, due to reduced sales and marketing and general and administrative expenses.
• The company's independent auditor has raised substantial doubt about the company's ability to continue as a going concern due to recurring losses and negative cash flows.
• As of December 31, 2023, the company had current assets of $156,132 and current liabilities of $2,057,049, indicating a significant working capital deficit.
• The company is in default on its convertible notes, with outstanding notes and loans totaling $1,954,595, including accrued interest.
• The company's ability to continue as a going concern is dependent on obtaining additional financing and generating positive cash flow.

Sentiment

Score: 3

Explanation: The document highlights significant financial challenges, including a net loss, going concern issues, and debt defaults. While there are some positive trends in revenue and gross margin, the overall outlook is negative from an investment perspective.

Positives

• The company's revenue increased by approximately 13% year-over-year.
• The company's gross profit margin improved from 49.8% to 56.3% year-over-year.
• Operating expenses decreased year-over-year, indicating improved cost management.
• The net loss decreased by over 50% year-over-year.

Negatives

• The company experienced a net loss of $468,362 in 2023.
• The company has a significant working capital deficit.
• The company is in default on its convertible notes.
• The company's independent auditor has raised concerns about its ability to continue as a going concern.

Risks

• The company's ability to continue as a going concern is uncertain due to recurring losses and negative cash flows.
• The company is highly leveraged with significant outstanding debt.
• The company is dependent on third parties for its products.
• The company operates in a highly competitive industry.
• The company is subject to extensive government regulations.
• The company's stock price is likely to be highly volatile.
• The company has identified material weaknesses in its internal controls.
• The company's sole officer and director has conflicts of interest due to other business activities.

Future Outlook

The company plans to increase revenues by charging physicians a monthly subscription fee for the use of QHSLab and soliciting additional healthcare providers to use their products. They also plan to introduce additional point of care diagnostics and treatments, and digital medicine programs.

Management Comments

• Management anticipates additional increases in operating expenses and capital expenditures relating to developmental and marketing expenses.
• Management expects that working capital requirements will continue to be funded through a combination of existing funds, further issuances of securities and borrowings.

Industry Context

The healthcare industry is increasingly adopting digital technologies to improve outcomes, access, and cost-effectiveness. QHSLab is positioned to capitalize on this trend by providing digital medicine solutions to primary care physicians.

Comparison to Industry Standards

• The company competes with companies like Phresia, Qure4U, Linus Health, Chadis, Yosi Health, Health Note, DarioHealth Corp and Noom, Inc., some of which market directly to consumers.
• Many of the company's competitors have greater resources, recognition, deeper customer relationships, larger existing customer bases, and more mature intellectual property portfolios.
• The company's gross margin of 56.3% is within the range of other SaaS and medical device companies, but its net loss indicates a need for improved profitability.
• The company's reliance on debt financing is a concern, as many successful companies in this sector have a stronger balance sheet.

Corporate Governance

Related Party Transactions

• The company is provided office space at no cost by an entity related to Troy Grogan.
• The company has received cash advances from its majority shareholder.

Stakeholder Impact

• Shareholders face significant risk due to the company's financial instability and potential dilution from future capital raises.
• Employees may be impacted by potential cost-cutting measures or restructuring.
• Customers may be affected by the company's ability to continue providing services.
• Creditors face the risk of not being repaid due to the company's debt defaults.

Next Steps

• The company intends to increase the number of physicians utilizing the QHSLab platform.
• The company plans to expand the number of diagnostic algorithms and health risk assessments incorporated into QHSLab.
• The company intends to add features which allow PCPs to engage in reimbursable forms of digital medicine.

Key Dates

Keywords

medical device, SaaS, digital health, allergy, immunotherapy, chronic disease, healthcare, software, QHSLab, financial results